Clinical trials: Recurrent Non Small Cell Lung Cancer
Non-Small-Cell Lung Cancer
Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer
Determine tumor response rate and time to disease progression, survival and safety in total populations.
- Trial name
- NCT00063388
- Testing
- Cetuximab
- Where
- 8 sites in United States
- Volunteers
- 66 people
- Sponsor
- Eli Lilly and Company
Non Small Cell Lung Carcinoma
ZD6474 Phase IIa Dose Finding Multicentre Study
To assess the objective response rates (by RECIST) to ZD6474 100, 200 and 300 mg/day respectively
- Trial name
- NCT00252746
- Testing
- ZD6474 (vandetanib) 100mg, ZD6474 (vandetanib) 200mg, ZD6474 (vandetanib) 300mg
- Where
- 7 sites in Japan
- Volunteers
- 53 people
- Sponsor
- Genzyme, a Sanofi Company
Cancer
Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation
RATIONALE: Antivirals such as ribavirin are used to treat infections caused by viruses. It is not yet known if ribavirin is more effective with or without monoclonal antibody therapy in treating patients who develop RSV pneumonia…
- Trial name
- NCT00014391
- Testing
- palivizumab, ribavirin
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Recurrent Non Small Cell Lung Cancer
APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer
This study will compare the anti-tumor efficacy of apricoxib and erlotinib with placebo and erlotinib as measured by time to disease progression to test the hypothesis that down regulation of COX-2 and EGFR pathways in patients…
- Trial name
- TP2001-201 (NCT00652340)
- Testing
- apricoxib/erlotinib
- Where
- 47 sites in United States
- Volunteers
- 120 people
- Sponsor
- Tragara Pharmaceuticals, Inc.
Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine ditartrate, work in different ways to stop the growth of tumor…
- Conditions
- Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma, Male Breast Cancer, Malignant Paraganglioma
- Trial name
- NCT01155258
- Testing
- temsirolimus, vinorelbine ditartrate
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Southern California
Cervical Cancer, Esophageal Cancer
Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of isotretinoin may be an effective way to prevent cancer or stop cancer from growing.
- Conditions
- Cervical Cancer, Esophageal Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00002506
- Testing
- recombinant interferon alfa, isotretinoin
- Where
- 6 sites in United States
- Sponsor
- Hoag Memorial Hospital Presbyterian
Non-small Cell Lung Cancer, Minimal Residual Disease
Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer
The goal of this study is to develop new techniques for minimal residual disease(MRD) monitoring and to confirm the efficacy and safety of MRD-guided postoperative management for early stage non-small cell lung cancer.
- Conditions
- Non-small Cell Lung Cancer, Minimal Residual Disease, Adaptive Treatment
- Trial name
- NCT06930807
- Testing
- Adaptive postoperative management based on minimal residual disease
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Peking University People's Hospital
Lung Cancer
Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer
The primary goal of this study is to determine the effects of the combination of Gleevec and Taxotere in lung cancer in terms of control and reduction of the cancer size.
- Trial name
- NCT00222144
- Testing
- Gleevec and Taxotere
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- University of Kansas
Non-small Cell Lung Cancer
Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Objectives: To determine the safety, tolerability, and efficacy of allogeneic PB103 in patients with IIIb/IV or refractory non-small-cell lung cancer
- Trial name
- NCT04616209
- Testing
- donor-derived NK cell infusion
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- Precision Biotech Taiwan Corp.
Lung Cancer
S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00436332
- Testing
- bevacizumab, erlotinib hydrochloride
- Where
- 148 sites in United States
- Volunteers
- 84 people
- Sponsor
- SWOG Cancer Research Network
Non-Small-Cell Lung Carcinoma
Iressa Versus Docetaxel (Taxotere)
The purpose of this study is to compare the effects of ZD1839 or docetaxel in patients with advanced non-small cell lung cancer (NSCLC) that has recurred or progressed after receiving prior treatment with platinum-based…
- Trial name
- NCT00076388
- Testing
- Gefitinib, Docetaxel
- Where
- 162 sites in United States, Argentina and 23 more
- Volunteers
- 1,440 people
- Sponsor
- AstraZeneca
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
Non-Small Cell Lung Cancer
Iressa 2nd Line Phase III Study in Japan
In this study, among the patients with non-small cell lung cancer, those with metastasis or recurrence and previous treatment with chemotherapy will receive gefitinib or docetaxel, and we will compare the effectiveness and safety…
- Trial name
- NCT00252707
- Testing
- Gefitinib or Docetaxel
- Where
- 40 sites in Japan
- Volunteers
- 484 people
- Sponsor
- AstraZeneca
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
This phase I trial studies the side effects and best dose of PBF-1129 in combination with nivolumab in treating patients with non-small cell lung cancer that has come back (recurrent) or spread to other places in the body…
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- NCT05234307
- Testing
- Adenosine A2B Receptor Antagonist PBF-1129, Biospecimen Collection, Nivolumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Dwight Owen
Lung Cancer
Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as docetaxel use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00064012
- Testing
- bortezomib, docetaxel
- Where
- 21 sites in United States
- Volunteers
- 4 people
- Sponsor
- University of Wisconsin, Madison
Lung Cancer
Gemcitabine Plus Carboplatin or Cisplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004201
- Testing
- carboplatin, cisplatin, gemcitabine hydrochloride
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer
A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)
The researchers think that the study drugs, amivantamab and lazertinib, may be an effective treatment for people who have metastatic NSCLC with an EGFR mutation.
- Trial name
- NCT04965090
- Testing
- Amivantamab, Lazertinib
- Where
- 7 sites in United States
- Volunteers
- 43 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non Small Cell Lung Cancer
Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung Cancer
The purpose of this study is to evaluate the safety, tolerability, immune response and clinical response of different doses of HLA-A*2402 restricted epitope peptides URLC10, CDCA1, VEGFR1 and VEGFR2 emulsified with Montanide ISA…
- Trial name
- NCT00874588
- Testing
- HLA-A*2402restricted URLC10, CDCA1, VEGFR1 and VEGFR2
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- Fukushima Medical University
Lung Cancer
Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00278460
- Testing
- docetaxel, gemcitabine hydrochloride
- Volunteers
- 49 people
- Sponsor
- Wake Forest University Health Sciences
Carcinoma, Non-Small-Cell Lung
LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer
The present trial will be performed to evaluate whether BIBF 1120 in combination with standard therapy of docetaxel in patients with stage IIIB/IV or recurrent NSCLC is more effective as compared to placebo in combination with…
- Trial name
- NCT00805194
- Testing
- BIBF 1120 plus docetaxel
- Where
- 210 sites in Austria, Belarus and 25 more
- Volunteers
- 1,314 people
- Sponsor
- Boehringer Ingelheim